Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Cancer Cachexia Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
-
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025
... cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Non-Melanoma Skin Cancer
... at a CAGR of 4.4% over the analysis period 2024-2030. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 Million by the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear Testing, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by ... Read More
-
Colposcopy
... 3.9% over the analysis period 2024-2030. Optical Instrument, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$580.3 Million by the end of the analysis period. Growth ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2025-2033
... 2025-2033. The increasing prevalence of the disease, advancements in personalized medicine, the emergence of new therapies, higher healthcare spending, and growing public awareness about prostate health and available treatment options are strengthening the market growth. ... Read More
-
Biomarkers Market Report by Product (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Renal Disorders, and Others), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, and Others), End User (Pharmaceutical and Biotechnology Companies, Diagnostic and Research Laboratories, Hospitals and Specialty Clinics, and Others), and Region 2025-2033
... rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers ... Read More
-
Nano-Magnetic Devices
... CAGR of 5.4% over the analysis period 2024-2030. Sensors, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$12.8 Billion by the end of the analysis period. ... Read More
-
Alpha Emitters
... CAGR of 20.9% over the analysis period 2024-2030. Bone Metastasis Application, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$993.8 Million by the end of the ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion ... Read More
-
Sunitinib Malate
... CAGR of 9.6% over the analysis period 2024-2030. Above 99% Purity, one of the segments analyzed in the report, is expected to record a 10.5% CAGR and reach US$120.6 Million by the end of the ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the end ... Read More
-
Dendritic Cell Cancer Vaccine Global Market Report 2025
... cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly ... Read More
-
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)
... are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending ... Read More
-
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2025
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Advanced Melanoma - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Advanced Melanoma: Understanding Advanced Melanoma: ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by the ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
Research Assistance
